What elephant?
We get it.
Itʼs something no one wants to talk
about.
It takes up half the room and no one
says a word.
How smart is it to invest in an industry
as new as ours?
How smart to invest in a company in
the same business as three-dozen other
companies doing the same thing?
Short answer: it isnʼt.
Which is why at GB Sciences weʼre not
doing the same thing.
And we may be the elephant in the
room, but weʼre tickled pink when
people start to notice.
About the GB Sciences elephant:
Our cultivation process has given us
higher yields per active flower light than
any other major grower in the Nevada
market. Call that the trunk. A trunk
whose revenue feeds our constantly
expanding cultivation capacity. Not
exactly peanuts.
Our proprietary tissue propagation
process minimizes genetic drift the way
an elephantʼs foot minimizes a ping pong
ball.
Speaking of feet, weʼve got ours
planted firmly in Nevada, with plans to
gbsciences
the future of healing
OTCQB: GBLX
www.gbsciences.com
trek across California, Texas and
Louisiana. Our sturdy legs will carry us
into the biggest markets in the US, where
thereʼs plenty of green to feed the beast.
And what about those big ears of
ours? Well, theyʼre always listening. To
science. Weʼre the only cannabis
company in the US to partner with a
major research university, LSU Agcenter,
to explore the plant and commercialize
tissue propagation. Now thatʼs a jumbo
sized business opportunity. And weʼre
starting in-human patient studies for our
Parkinsonʼs formulations this year. Of
course, our big brains help a lot there.
So, go ahead, talk all you want about
the elephant in the room.
Then hop on and come along for the
ride.
This elephant has a lot of room left to
cover.